<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Bristol-Myers Squibb ( BMY , Financial) seems to be on track for a solid year in 2022, fueled by strong sales of core drugs Eliquis and Opdivo, as well as continued demand growth for their new products. The company’s launch of Zeposia in the U.S. for ulcerative colitis has progressed smoothly, and they recently received European approval for the same during the past quarter.
...read full article on GuruFocus
